Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2023 Filed Jan 28, 2023 00:15 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 2 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · derivative · entry 12 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 1,696 | $33.29 | $56,459.33 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 9 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.66, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 13,304 | $32.40 | $431,057.58 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 8 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,508 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.95 to $32.90, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 7 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Coulie BernardDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 206,300 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003177 · form4.xml · derivative · entry 10 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,300 Underlying: Common Stock · 206,300 shares Expires 2033-01-24 F9 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Coulie BernardDirector · President and CEO
|
GrantCommon Stock | 146,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 1 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,112 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003181 · form4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-24 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Cummings Keith LamontChief Financial Officer
|
GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003181 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,424 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC |
Lefebvre EricChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003178 · form4.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-01-24 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC |
Lefebvre EricChief Medical Officer
|
GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003178 · form4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,926 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC |
Hull HansChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003180 · form4.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-24 F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC |
Hull HansChief Business Officer
|
GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003180 · form4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,191 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003179 · form4.xml · derivative · entry 2 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-01-24 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003179 · form4.xml · nonDerivative · entry 1 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,947 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · derivative · entry 11 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 15,000 | $30.89 | $463,389.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 6 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.42 to $31.38, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 5 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · derivative · entry 5 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,198 Underlying: Common Stock · 17,500 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · derivative · entry 4 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,597 Underlying: Common Stock · 12,500 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Cummings Keith LamontChief Financial Officer
|
SaleCommon Stock | 30,000 | $35.00 | $1,050,000.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 3 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 5, 2021, as amended on August 29, 2022. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionCommon Stock | 17,500 | $6.22 | $108,850.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionCommon Stock | 12,500 | $2.08 | $26,000.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · derivative · entry 10 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 15,000 | $35.00 | $525,000.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 4 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 434,317 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F5 · ownership.nature: Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 4,850 | $34.93 | $169,404.68 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 3 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.43 to $35.00, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 10,150 | $33.71 | $342,162.59 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 2 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,662 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.40 to $34.34, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-002786 · form4.xml · nonDerivative · entry 1 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:00 UTC |
Lefebvre EricChief Medical Officer
|
SaleCommon Stock | 67,500 | $34.48 | $2,327,629.50 |
DisclosureSEC source: 0001140361-23-002784 · form4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,926 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001140361-23-002785 · form4.xml · derivative · entry 5 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,240 Underlying: Common Stock · 10,000 shares Expires 2030-10-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to such option vested on October 1, 2021 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001140361-23-002785 · form4.xml · derivative · entry 4 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
SaleCommon Stock | 20,000 | $34.19 | $683,878.00 |
DisclosureSEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 3 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,947 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
Exercise / conversionCommon Stock | 10,000 | $24.32 | $243,200.00 |
DisclosureSEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 2 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
Exercise / conversionCommon Stock | 10,000 | $11.86 | $118,600.00 |
DisclosureSEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 1 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:00 UTC |
Cheung LilyChief Human Resource Officer
|
GrantStock Option (Right to Buy) · Derivative | 123,000 | $0.00 Strike: $21.94 | $0.00 |
DisclosureSEC source: 0001140361-23-002451 · form4.xml · derivative · entry 1 Cheung Lily · CIK 0001962207 · Chief Human Resource Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,000 Underlying: Common Stock · 123,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: 25% of the shares subject to such option vest on January 19, 2024 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · derivative · entry 7 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,380 Underlying: Common Stock · 5,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 5,000 | $19.17 | $95,829.00 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · nonDerivative · entry 4 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $2.08 | $10,400.00 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · nonDerivative · entry 3 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · derivative · entry 6 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 15,000 | $19.04 | $285,583.50 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · nonDerivative · entry 2 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 01:16 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-001119 · form4.xml · nonDerivative · entry 1 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · derivative · entry 7 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 15,000 | $19.06 | $285,940.50 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · nonDerivative · entry 4 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.185, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · nonDerivative · entry 3 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · derivative · entry 6 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,380 Underlying: Common Stock · 15,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
SaleCommon Stock | 15,000 | $19.33 | $289,951.50 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · nonDerivative · entry 2 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.80, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:44 UTC |
Coulie BernardDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0001140361-23-000721 · form4.xml · nonDerivative · entry 1 Coulie Bernard · CIK 0001808895 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 23, 2022 22:34 UTC |
Ouimette MikeGeneral Counsel & Corp. Sec'y
|
SaleCommon Stock | 2,928 | $19.38 | $56,730.88 |
DisclosureSEC source: 0001140361-22-046917 · form4.xml · nonDerivative · entry 1 Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,947 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.57, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:30 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-22-047041 · form4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,097 Underlying: Common Stock · 4,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:30 UTC |
Cummings Keith LamontChief Financial Officer
|
Exercise / conversionCommon Stock | 4,000 | $2.08 | $8,320.00 |
DisclosureSEC source: 0001140361-22-047041 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.